Supernus (SUPN) Stock Price & Analysis

SUPN$29.72+0.52 +1.78%
Drug Manufacturers - Specialty & GenericGrowth Stock
Compare
Market cap$1.73BEnterprise value$1.72BRevenue (TTM)$1.37BMarket position—

Score

59
Neutral
Value
57
Quality
35
Growth
86

AI Analysis

Snapshot

Supernus mixes growth with a still-reasonable multiple — Growth 86/100 with P/E 7.1, about 67% below its own multi-year median. Under the hood: P/E 7.1, about 67% below its own multi-year median, plus revenue compounding ~11% annually over recent years. Street targets still imply ~60% upside.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

57
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

86
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

35
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Supernus, Inc. (SUPN) last printed $29.72. Equity value is $1.73B. Trailing earnings multiple 7.79. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$968.89M$1.15B$959.92M$785M$647M$791M$901M$1.09B$1.19B$1.24B

About

Supernus, Inc. is a diversified biopharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) diseases. Its portfolio of 11 marketed products spans opioid use disorder, psychiatry, and neurology, and includes SUBLOCADE, a long-acting injectable buprenorphine for opioid use disorder, along with sublingual OUD treatments; Qelbree, a non-stimulant treatment for attention-deficit hyperactivity disorder (ADHD); GOCOVRI for dyskinesia in Parkinson’s disease patients receiving levodopa-based therapy; ONAPGO for motor fluctuations in advanced Parkinson’s disease; ZURZUVAE for postpartum depression; and treatments for epilepsy, migraine, cervical dystonia, and chronic sialorrhea, including Oxtellar XR, Trokendi XR, APOKYN, and MYOBLOC. The company also advances a pipeline of novel CNS product candidates. Its products are sold primarily in the United States, with additional markets including Canada, Australia, France, and Germany. The company was formed through the November 2026 merger of Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc., and is headquartered in Rockville, Maryland.

Supernus (SUPN) Stock Price & Analysis

SUPN price $29.72 +0.52 +1.78%

Ticker
SUPN
Price
$29.72
Change
+0.52 +1.78%
Market cap
$1.73B
P/E
7.79
Forward P/E
13.26
Dividend yield
0.31%
Beta
0.52
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stocklytics score
59
Value
57
Quality
35
Growth
86

Stocklytics score rationale: value 57, quality 35, growth 86.

Insights · Forecast · Financials · Learn

Stocklytics home · Screener